Overview

MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants

Status:
Terminated
Trial end date:
2014-12-19
Target enrollment:
Participant gender:
Summary
A single-centre, open-label, study using induced blood stage malaria infection to characterize the activity of MMV390048 against early Plasmodium falciparum blood stage infection.
Phase:
Phase 1
Details
Lead Sponsor:
Medicines for Malaria Venture
Collaborator:
Q-Pharm Pty Limited